| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, New Jersey
A microsporidian infection of low pathogenicity in mice has been found to retard the growth of a variety of transplantable tumors and significantly prolong survival of hosts, including those bearing carcinogen-induced tumors. Resistance to tumor development remained after the hosts had recovered from the infection, but gradually waned with time. The infection did not induce resistance to Salmonella. The possible mechanisms by which the protozoan infection affects tumor development are discussed.
1 This investigation was supported in part by the Cancer Chemotherapy National Service Center, National Cancer Institute, under the NIH Contract No. PH-43-64-883.
Received 12/ 2/65.
Revised 4/ 6/66.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |